Literature DB >> 20168333

TRAIL-activated stress kinases suppress apoptosis through transcriptional upregulation of MCL-1.

J K Son1, S Varadarajan, S B Bratton.   

Abstract

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a potentially useful anticancer agent with exquisite selectivity for cancer cells. Unfortunately, many cancers show or acquire resistance to TRAIL. In this study we report that TRAIL activates a TGF-beta-activated kinase 1 --> mitogen-activated protein kinase (MAPK) kinase 3 (MKK3)/MKK6 --> p38 pathway in prostate cancer cells that transcriptionally upregulates expression of the antiapoptotic BCL-2 family member MCL-1. TRAIL alone triggered robust formation of the 'death-inducing signaling complex' (DISC), activation of the initiator caspase-8, and truncation of the BH3-only protein BID (tBID). Nevertheless, simultaneous disruption of the p38 MAPK pathway was required to suppress MCL-1 expression, thereby allowing tBID to activate the proapoptotic BCL-2 family member BAK and stimulate mitochondrial outer membrane permeabilization (MOMP). Release of the inhibitor-of-apoptosis (IAP) antagonist, Smac/DIABLO, from the intermembrane space was sufficient to promote TRAIL-induced apoptosis, whereas release of cytochrome c and activation of the apoptosome was dispensable. Even after MOMP, however, mitochondrial-generated reactive oxygen species (ROS) activated a secondary signaling pathway, involving c-Jun N-terminal kinases (JNKs), that similarly upregulated MCL-1 expression and partially rescued some cells from death. Thus, stress kinases activated at distinct steps, before and after mitochondrial injury, mediate TRAIL resistance through maintenance of MCL-1 expression.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20168333      PMCID: PMC3638721          DOI: 10.1038/cdd.2010.9

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  55 in total

1.  Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function.

Authors:  Lin Chen; Simon N Willis; Andrew Wei; Brian J Smith; Jamie I Fletcher; Mark G Hinds; Peter M Colman; Catherine L Day; Jerry M Adams; David C S Huang
Journal:  Mol Cell       Date:  2005-02-04       Impact factor: 17.970

2.  Mule/ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the polyubiquitination of Mcl-1 and regulates apoptosis.

Authors:  Qing Zhong; Wenhua Gao; Fenghe Du; Xiaodong Wang
Journal:  Cell       Date:  2005-07-01       Impact factor: 41.582

3.  Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1.

Authors:  Ulrich Maurer; Céline Charvet; Allan S Wagman; Emmanuel Dejardin; Douglas R Green
Journal:  Mol Cell       Date:  2006-03-17       Impact factor: 17.970

4.  Obligate role of anti-apoptotic MCL-1 in the survival of hematopoietic stem cells.

Authors:  Joseph T Opferman; Hiromi Iwasaki; Christy C Ong; Heikyung Suh; Shin-ichi Mizuno; Koichi Akashi; Stanley J Korsmeyer
Journal:  Science       Date:  2005-02-18       Impact factor: 47.728

5.  Reactive oxygen species promote TNFalpha-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases.

Authors:  Hideaki Kamata; Shi-Ichi Honda; Shin Maeda; Lufen Chang; Hajime Hirata; Michael Karin
Journal:  Cell       Date:  2005-03-11       Impact factor: 41.582

6.  TAK1 is recruited to the tumor necrosis factor-alpha (TNF-alpha) receptor 1 complex in a receptor-interacting protein (RIP)-dependent manner and cooperates with MEKK3 leading to NF-kappaB activation.

Authors:  Marzenna Blonska; Prashant B Shambharkar; Masayuki Kobayashi; Dongyu Zhang; Hiroaki Sakurai; Bing Su; Xin Lin
Journal:  J Biol Chem       Date:  2005-10-31       Impact factor: 5.157

7.  Use of a drug-resistant mutant of stress-activated protein kinase 2a/p38 to validate the in vivo specificity of SB 203580.

Authors:  P A Eyers; P van den IJssel; R A Quinlan; M Goedert; P Cohen
Journal:  FEBS Lett       Date:  1999-05-21       Impact factor: 4.124

8.  Molecular determinants of kinase pathway activation by Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand.

Authors:  Eugene Varfolomeev; Heather Maecker; Darcie Sharp; David Lawrence; Mark Renz; Domagoj Vucic; Avi Ashkenazi
Journal:  J Biol Chem       Date:  2005-10-15       Impact factor: 5.157

9.  XIAP discriminates between type I and type II FAS-induced apoptosis.

Authors:  Philipp J Jost; Stephanie Grabow; Daniel Gray; Mark D McKenzie; Ueli Nachbur; David C S Huang; Philippe Bouillet; Helen E Thomas; Christoph Borner; John Silke; Andreas Strasser; Thomas Kaufmann
Journal:  Nature       Date:  2009-07-22       Impact factor: 49.962

10.  Genetically encoded fluorescent indicator for intracellular hydrogen peroxide.

Authors:  Vsevolod V Belousov; Arkady F Fradkov; Konstantin A Lukyanov; Dmitry B Staroverov; Konstantin S Shakhbazov; Alexey V Terskikh; Sergey Lukyanov
Journal:  Nat Methods       Date:  2006-04       Impact factor: 28.547

View more
  18 in total

1.  Quercetin-mediated Mcl-1 and survivin downregulation restores TRAIL-induced apoptosis in non-Hodgkin's lymphoma B cells.

Authors:  Guillaume Jacquemin; Virginie Granci; Anne Sophie Gallouet; Najoua Lalaoui; Aymeric Morlé; Elisabetta Iessi; Alexandre Morizot; Carmen Garrido; Thierry Guillaudeux; Olivier Micheau
Journal:  Haematologica       Date:  2011-09-20       Impact factor: 9.941

Review 2.  Targeting TNF-related apoptosis-inducing ligand (TRAIL) receptor by natural products as a potential therapeutic approach for cancer therapy.

Authors:  Xiaoyun Dai; Jingwen Zhang; Frank Arfuso; Arunachalam Chinnathambi; M E Zayed; Sulaiman Ali Alharbi; Alan Prem Kumar; Kwang Seok Ahn; Gautam Sethi
Journal:  Exp Biol Med (Maywood)       Date:  2015-04-07

Review 3.  Surviving apoptosis: life-death signaling in single cells.

Authors:  Deborah A Flusberg; Peter K Sorger
Journal:  Trends Cell Biol       Date:  2015-04-25       Impact factor: 20.808

4.  UMI-77 primes glioma cells for TRAIL-induced apoptosis by unsequestering Bim and Bak from Mcl-1.

Authors:  Ji-Wei Liu; Zhi-Chuan Zhu; Kui Li; Hong-Tao Wang; Zhi-Qi Xiong; Jing Zheng
Journal:  Mol Cell Biochem       Date:  2017-03-23       Impact factor: 3.396

5.  Antiapoptotic signaling via MCL1 confers resistance to caspase-3-mediated apoptotic cell death in the pregnant human uterine myocyte.

Authors:  Alyssa Stephenson-Famy; Jason Marks; Arvind Suresh; Stanley N Caritis; Hygraiv Simhan; Pancharatnam Jeyasuria; Jennifer C Condon
Journal:  Mol Endocrinol       Date:  2011-12-22

6.  miR-22 and miR-29a Are Members of the Androgen Receptor Cistrome Modulating LAMC1 and Mcl-1 in Prostate Cancer.

Authors:  Lorenza Pasqualini; Huajie Bu; Martin Puhr; Narisu Narisu; Johannes Rainer; Bettina Schlick; Georg Schäfer; Mihaela Angelova; Zlatko Trajanoski; Stefan T Börno; Michal R Schweiger; Christian Fuchsberger; Helmut Klocker
Journal:  Mol Endocrinol       Date:  2015-06-08

7.  The PI3 kinase inhibitor NVP-BKM120 induces GSK3/FBXW7-dependent Mcl-1 degradation, contributing to induction of apoptosis and enhancement of TRAIL-induced apoptosis.

Authors:  Hui Ren; Liqun Zhao; Yikun Li; Ping Yue; Xingming Deng; Taofeek K Owonikoko; Mingwei Chen; Fadlo R Khuri; Shi-Yong Sun
Journal:  Cancer Lett       Date:  2013-04-02       Impact factor: 8.679

Review 8.  Non-canonical kinase signaling by the death ligand TRAIL in cancer cells: discord in the death receptor family.

Authors:  K Azijli; B Weyhenmeyer; G J Peters; S de Jong; F A E Kruyt
Journal:  Cell Death Differ       Date:  2013-04-12       Impact factor: 15.828

9.  SB202190-induced cell type-specific vacuole formation and defective autophagy do not depend on p38 MAP kinase inhibition.

Authors:  Manoj B Menon; Alexey Kotlyarov; Matthias Gaestel
Journal:  PLoS One       Date:  2011-08-10       Impact factor: 3.240

10.  The downregulation of Mcl-1 via USP9X inhibition sensitizes solid tumors to Bcl-xl inhibition.

Authors:  Chander Peddaboina; Daniel Jupiter; Steven Fletcher; Jeremy L Yap; Arun Rai; Richard P Tobin; Weihua Jiang; Philip Rascoe; M Karen Newell Rogers; W Roy Smythe; Xiaobo Cao
Journal:  BMC Cancer       Date:  2012-11-21       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.